{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003885","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.498879+00:00","generated_at":"2026-06-07T02:27:23.078999+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Acrivon updates corporate presentation at JPM; confirms cash runway into H2 2025","bullets":["Participates in 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024.","Updated corporate presentation includes product candidate development progress.","Confirms projected cash runway into the second half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003885","json":"https://secwatch.observer/filing/0001193125-24-003885.json","markdown":"https://secwatch.observer/filing/0001193125-24-003885.md","text":"https://secwatch.observer/filing/0001193125-24-003885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312524003885/0001193125-24-003885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312524003885/d103829d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:27:23.078999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}